Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease
复制标题
DOI：
10.14309/ajg.0000000000000830
复制
发表时间：
2020-10-01
影响因子：
9.8
通讯作者：
Tursi, Antonio
中科院分区：
文献类型：
--
作者：
Papa, Alfredo;Gasbarrini, Antonio;Tursi, Antonio
简介：据推测，患有炎症性肠病（IBD）的人患冠状病毒病（COVID-19）的风险增加。然而，目前尚不清楚免疫抑制治疗是否会加剧COVID-19的结局。方法：我们回顾了IBD患者中COVID-19的患病率和临床结局的数据。结果：IBD患者中COVID-19的患病率与普通人群相当。使用抗肿瘤坏死因子-α药物的治疗与更好的临床outcomes.Discussion：胃肠病学家提供的管理和治疗有效降低COVID-19风险。抗肿瘤坏死因子-α药物似乎可以缓解COVID-19的病程。
INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome.METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD.RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-alpha agents have been associated with better clinical outcomes.DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-alpha agents seem to mitigate the course of COVID-19.